A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis?

Microbes and Infection

Volumn 10, Issue 9, 2008, Pages 1051-1056

  Locht, Camille ^a,b  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Pertussis; Prime boost; Tuberculosis; Vaccination

Indexed keywords

ACELLULAR VACCINE; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; FILAMENTOUS HEMAGGLUTININ; HEMAGGLUTININ; HEPARIN BINDING HEMAGGLUTININ; LIVE VACCINE; MYCOBACTERIUM VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL VIRULENCE; BCG VACCINATION; BORDETELLA PERTUSSIS; BRAIN DISEASE; CAUSE OF DEATH; CELLULAR IMMUNITY; COMPARATIVE GENOMIC HYBRIDIZATION; CRYING; DEATH; DROWSINESS; EXTRAPULMONARY TUBERCULOSIS; FEBRILE CONVULSION; FEVER; GRAM NEGATIVE BACTERIUM; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LUNG TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; BCG VACCINE; BORDETELLA PERTUSSIS; HUMANS; IMMUNIZATION, SECONDARY; MYCOBACTERIUM TUBERCULOSIS; PERTUSSIS VACCINE; TUBERCULOSIS; TUBERCULOSIS VACCINES; WHOOPING COUGH;

BORDETELLA PERTUSSIS;

EID: 53449093310     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.07.008     Document Type: Article

References (48)

1. http://www.who.int/tb/publications/global_report/2008/en/index.html
2. Mehta J.B., Dutt A., Harvill L., and Mathews K.M. Epidemiology of extrapulmonary tuberculosis. A comparative analysis with pre-AIDS era. Chest 99 (1991) 1134-1138
3. Cruz A.T., and Starke J.R. Clinical manifestations of tuberculosis in children. Paediatr. Respir. Rev. 8 (2007) 107-117
4. Raviglione M.C., and Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 350 (2002) 624-629
5. Shah N.S., Wright A., Bai G.H., Barrera L., Boulahbal F., Martin-Casadona N., Drobniewski F., Gilpin C., Havelkova M., Lepe R., Lumb R., Metchock B., Portaels F., Rodrigues M.F., Rüsch-Gerdes S., Van Deun A., Vincent V., Laserson K., Wells C., and Cegielski J.P. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13 (2007) 380-387
6. Forsyth K.D., Wirsing von König C.-H., Tan T., Caro J., and Plotkin S. Prevention of pertussis: recommendations derived from the second global pertussis initiative roundtable meeting. Vaccine 25 (2007) 2634-2642
7. Baughman A.L., Cortese M.M., and Slade B.A. Incidence of Bordetella pertussis infection in adolescents and adults. Clin. Infect. Dis. 44 (2007) 149-150
8. Mahon B.P., Sheahan B.J., Griffin F., Murphy G., and Mills K.H.G. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-γ receptor or immunoglobulin μ chain genes. J. Exp. Med. 186 (1997) 1843-1851
9. Byrne P., McGuirk P., Todryk S., and Mills K.H. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur. J. Immunol. 34 (2004) 2579-2588
10. Locht C., Antoine R., and Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr. Opin. Microbiol. 4 (2001) 82-89
11. Stibitz S. The bvg regulon. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, UK 47-67
12. Wirsing von König C.-H. Use of antibiotics in the prevention and treatment of pertussis. Pediatr. Infect. Dis. J. 24 (2005) S66-S68
13. Tozzi A.E., Celentano L.P., Ciofi degli Atti M.L., and Salmaso S. Diagnosis and management of pertussis. CMAJ 172 (2005) 509-515
14. Calmette A. La vaccination préventive contre la tuberculose (1927), Masson et Cie, Paris 250p
15. Talbot E.A., Perkins M.D., Silva S.F., and Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin. Infect. Dis. 24 (1997) 1139-1146
16. Casanova J.L., and Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20 (2002) 581-620
17. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., and Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. J. Am. Med. Assoc. 271 (1994) 698-702
18. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., and Small P.M. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
19. Lopez B., Aguilar D., Orozco H., Burger M., Espitia C., Ritacco V., Barrera L., Kremer K., Hernandez-Pando R., and Huygen K. D. van Soolingen, A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 133 (2003) 30-37
20. Brandt L., Feino Cunha J., Weinreich Olsen A., Chilima B., Hirsch P., Appelberg R., and Andersen P. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70 (2002) 672-678
21. Rodrigues L.C., Pereira S.M., Cunha S.C., Genser B., Ichihara M.Y., de Brito S.C., Hijjar M.A., Dourado I., Cruz A.A., Sant'Anna C., Bierrenbach A.L., and Barreto M.L. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366 (2005) 1290-1295
22. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., Dos Santos S., Duthoy S., Lacroix C., Garcia-Pelayo C., Inwald J.K., Golby P., Nunez Garcia J., Hewinson R.G., Behr M.A., Quail M.A., Churcher C., Barrell B.G., Parkhill J., and Cole S.T. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA 104 (2007) 5596-5601
23. Brodin P., Rosenkrands I., Andersen P., Cole S.T., and Brosch R. ESAT-6 proteins: protective antigens and virulence facors?. Trends Microbiol. 12 (2004) 500-508
24. Pym A.S., Brodin P., Brosch R., Huerre M., and Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46 (2002) 709-717
25. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., Griffiths K.E., Marchal G., Leclerc C., and Cole S.T. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9 (2003) 533-539
26. Horwitz M.A., Harth G.A., Dillon B.J., and Maslesa-Galic' S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97 (2000) 13853-13858
27. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., Bandermann S., Smith D., Bancroft G.J., Reyrat J.M., van Soolingen D., Raupach B., and Kaufmann S.H. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115 (2005) 2472-2479
28. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., Ausina V., and Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 (2006) 3408-3419
29. Storsaeter J., Wolter J., and Locht C. Pertussis vaccines. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, U.K. 245-288
30. Sato Y., Kimura M., and Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1 (1984) 122-126
31. Grimprel E., Baron S., Levy-Bruhl D., Garnier J.M., N'jamkepo E., Guiso N., and Begue P. Influence of vaccination coverage on pertussis transmission in France. Lancet 354 (1999) 1699-1700
32. Campons-Marti M., Cheng H.K., Forsyth K., Guiso N., Halperin S., Huang L.M., Mertsola J., Oselka G., Ward J., Wirsing von König C.-H., and Zepp F. International consensus group on pertussis immunisation, recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20 (2001) 641-646
33. Rennels M.B. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin. Pediatr. Infect. Dis. 14 (2003) 196-198
34. Rowe J., Yerkovich S.T., Richmond P., Suriyaarachchi D., Fischer E., Feddema L., Loh R., Sly P.D., and Holt P.G. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun. 73 (2005) 8130-8135
35. Vergara R., Tregnaghi M., Ussher J., Navarro S., Ruttiman R., Potin M., Wolter J., and Schuerman L. Reduced-antigen-content-diptheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur. J. Pediatr. 164 (2005) 377-382
36. Siegrist C.-A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
37. Mills K.H.G. Immunity to Bordetella pertussis. Microb. Infect. 3 (2001) 655-677
38. Mascart F., Verscheure V., Malfroot A., Hainaut M., Piérard D., Temmerman S., Peltier A., Debrie A.-S., Levy J., Del Giudice G., and Locht C. Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J. Immunol. 170 (2003) 1504-1509
39. Mielcarek N., Debrie A.-S., Raze D., Bertout J., Rouanet C., Ben Younes A., Creusy C., Engle J., Goldman W.E., and Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathogens 2 (2006) e65
40. http://www.child-innovac.org
41. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., and Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior Bacillus Calmette-Guérin immunity. J. Immunol. 177 (2006) 6353-6360
42. http://www.TBVAC.org
43. Hougardy J.M., Schepers K., Place S., Drowart A., Lechevin V., Verscheure V., Debire A.-S., Doherty T.M., Van Vooren J.P., Locht C., and Mascart F. Heparin-binding hemagglutinin-induced IFN-γ release as a diagnostic tool for latent tuberculosis. PLoS One 2 (2007) e926
44. Menozzi F.D., Rouse J.H., Alavi M., Laude-Sharp M., Muller J., Bischoff R., Brennan M.J., and Locht C. Identification of a heparin-binding hemagglutinin present in mycobacteria. J. Exp. Med. 184 (1996) 993-1001
45. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., and Menozzi F.D. The Heparin-binding haemagglutinin of Mycobacterium tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
46. Masungi C., Temmerman S., Van Vooren J.P., Drowart A., Pethe K., Menozzi F.D., Locht C., and Mascart F. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J. Infect. Dis. 185 (2002) 513-520
47. +T lymphocytes in latent human tuberculosis. J. Infect. Dis. 192 (2005) 226-232
48. Temmerman S., Pethe K., Parra M., Alonso S., Rouanet C., Pickett T., Drowart A., Debrie A.-S., Delogu G., Menozzi F.D., Sergheraert C., Brennan M.J., Mascart F., and Locht C. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat. Med. 10 (2004) 935-941